We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Stem Cell Innovations Signs Compound Validation Collaboration with H. Lundbeck

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Stem Cell Innovations Signs Compound Validation Collaboration with H. Lundbeck"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Stem Cell Innovations, Inc. has announced that it had entered into an agreement to examine hepatic metabolism of a set of Lundbeck compounds using its proprietary C3A human liver cell-line.

Lundbeck is a research-based pharmaceutical company, engaged in research to find new drugs for treatment of CNS disorders.

“This new collaboration shows the expanding acceptance of our C3A cell-line as an excellent platform to study human liver function,” said Stem Cell Innovations’ CEO Dr. James Kelly.

“Our protected C3A cell system has intact human liver machinery, is robust and thoroughly quality controlled, all the prerequisites for larger scale in vitro efficacy and safety programs,” Kelly added.

C3A is SCI’s patented human liver cell line, originally developed for use in an artificial liver used to support patients waiting for transplantation. The cells exhibit a wide variety of human liver functions and are ideal for use in examining the effects of new drugs on the human liver.

The application of SCI’s ACTIVTox system, based on the C3A cell line, can lead to better drugs with a decreased likelihood of causing liver toxicity.